While nnAb effects in influenza, cytomegalovirus (CMV), Ebola, and HIV-1 infections (Bournazos and Ravetch, 2017; Holl et al., 2009; Nimmerjahn et al., 2015) have been attributed to Fc-mediated effector functions (Horwitz et al., 2017; Mayr et al., 2017b; Nimmerjahn et al., 2015), nnAb anti-LCMV protection was consistently found to operate independently of FcγR or complement (Bergthaler et al., 2009; Richter and Oxenius, 2013; Straub et al., 2013). The gene discussed is FCGR2A; the disease is Ebola hemorrhagic fever.